Aeterna Zentaris (AEZS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
May 8, 2017 4:30 PM EDTAll amounts are in US Dollars
Highlights
Company reported on May 1 that ZoptEC Phase 3 clinical study of ZoptrexTM (zoptarelin doxorubicin) did not achieve its primary endpoint; further development of product to be discontinued
Company announced on March 30 that, following its meeting with the FDA it intends to file a new drug application seeking approval of MacrilenTM (macimorelin) for the evaluation of growth hormone deficiency in adults
Adequate liquidity and resources to fund operations through expected Macrilen approval
$17.8 million of unrestricted... More